InvestorsHub Logo
Followers 30
Posts 4142
Boards Moderated 0
Alias Born 07/25/2007

Re: 57_2001 post# 5839

Friday, 02/05/2021 3:26:34 AM

Friday, February 05, 2021 3:26:34 AM

Post# of 6214
VXRT has a tough slog ahead. The point is we know how to measure vaccine efficacy based on neutralizing antibody production, not so for T-cells. They are going to have to do a large (expensive) phase III trial and it is unlikely it can happen in the US or other developed countries as more vaccines get approved based on their phase III trials. Who is going to volunteer for an unproven vaccine when proven ones are available?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VXRT News